MC1R germline variants confer risk for BRAF-mutant melanoma

Science

Volumn 313, Issue 5786, 2006, Pages 521-522

  Landi, Maria Teresa ^a   Bauer, Jürgen ^b,c   Pfeiffer, Ruth M ^a   Elder, David E ^d   Hulley, Benjamin ^a   Minghetti, Paola ^e   Calista, Donato ^e   Kanetsky, Peter A ^d   Pinkel, Daniel ^b   Bastian, Boris C ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e BUFALINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GENES; GENETIC ENGINEERING; RADIATION DAMAGE; RISK ASSESSMENT; SKIN;

BRAF-MUTANT MELANOMA; CHRONIC SUN-INDUCED DAMAGE (CSD); MELANOCORTIN-1 RECEPTOR; SUN EXPOSURE;

MUTAGENS;

DNA; MELANOCORTIN 1 RECEPTOR;

GENE EXPRESSION; MELANISM; MUTATION; SKIN DISORDER; TUMOR;

ACTINIC ELASTOSIS; ALLELE; ARTICLE; BRAF GENE; CANCER RISK; CAUCASIAN; CONTROLLED STUDY; ELASTOSIS; EXON; GENE; GENE MUTATION; GENETIC RISK; GENETIC VARIABILITY; GERM LINE; HUMAN; ITALY; LONG TERM EXPOSURE; MC1R GENE; MELANOMA; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; RISK FACTOR; SUN EXPOSURE; SUNLIGHT; ULTRAVIOLET RADIATION;

ADOLESCENT; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; ITALY; MALE; MELANOMA; MIDDLE AGED; MUTATION; ODDS RATIO; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, MELANOCORTIN, TYPE 1; SKIN; SKIN NEOPLASMS; SUNLIGHT; UNITED STATES; VARIATION (GENETICS);

CAUCASUS; EURASIA;

EID: 33746589029     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1127515     Document Type: Article

References (18)

1. D. C. Whiteman et al., J. Natl. Cancer Inst. 95, 806 (2003).
2. V. Siskind, D. C. Whiteman, J. F. Aitken, N. G. Martin, A. C. Green, Cancer Causes Control 16, 193 (2005).
3. J. L. Maldonado et al., J. Natl. Cancer Inst. 95, 1878 (2003).
4. J. A. Curtin et al., New Eng. J. Med. 353, 2135 (2005).
5. V. Chhajlani, J. E. Wikberg, FEBS Lett. 309, 417 (1992).
6. F. Rouzaud, A. L. Kadekaro, Z. A. Abdel-Malek, V. J. Hearing, Mutat Rs. 571, 133 (2005).
7. L. Naysmith et al., J. Invest. Dermatol. 122, 423 (2004).
8. D. L. Duffy et al., Hum. Mol. Genet. 13, 447 (2004).
9. P. Valverde et al., Hum. Mol. Genet. 5, 1663 (1996).
10. J. S. Palmer et al., Am. J. Hum. Genet. 66, 176 (2000).
11. C. Kennedy et al., J. Invest. Dermatol. 117, 294 (2001).
12. M. T. Landi et al., J. Natl. Cancer Inst. 97, 998 (2005).
13. M. T. Landi et al., Br. J. Cancer 85, 1304 (2001).
14. Materials and. methods are available as supporting material on Science Online.
15. A. V. Brenner, J. H. Lubin, D. Calista, M. T. Landi, Am. J. Epidemiol. 156, 353 (2002).
16. M. C. Scott et al., J. Cell Sci. 115, 2349 (2002).
17. K. Wakamatsu et al., Pigment Cell Res. 19, 154 (2006).
18. We thank A. M. Goldstein and M. Tucker for helpful discussions. This study was supported by the Intramural Research Program of NIH, National Cancer Institute, Division of Cancer Epidemiology and Genetics, and by National Cancer Institute grants RO1 CA5558 to M.T.L., R33 CA95300 and PO1 CA025874-25-A1 to B.C.B., RO1 CA94963 to D.P., K07 CA80700 to P.A.K., and Deutsche Forschungsgemeinschaft stipend BA 2852/1-1 to J.B.